Berall v. Verathon Inc.

CourtDistrict Court, S.D. New York
DecidedJuly 11, 2022
Docket1:10-cv-05777
StatusUnknown

This text of Berall v. Verathon Inc. (Berall v. Verathon Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Berall v. Verathon Inc., (S.D.N.Y. 2022).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK JONATHAN BERALL, M.D., M.P.H., Plaintiff, No. 10-CV-5777 (LAP) -against- MEMORANDUM & ORDER TELEFLEX MEDICAL INCORPORATED, Defendant.

LORETTA A. PRESKA, Senior United States District Judge: Before the Court is Defendant Teleflex Medical Incorporated’s (“Teleflex”) motion to dismiss1 Plaintiff Dr. Jonathan Berall’s (“Dr. Berall”) Second Amended Complaint2 for improper venue, pursuant to Federal Rule of Civil Procedure 12(b)(3), or, in the alternative, to transfer venue, pursuant to 28 U.S.C. § 1406(a).3 Plaintiff opposed the motion,4 and Teleflex responded.5 For the reasons set forth below, Teleflex’s motion to dismiss is granted; the instant case shall be

1 (See Teleflex’s Mot. to Dismiss or Alternatively to Transfer Venue in Response to Pl’s. Second Am. Compl. (“MTD”), dated Dec. 2, 2021) [dkt. no. 359].) All citations to docket entries herein refer to 10-cv-5777. 2 (See Second Am. Compl. (“SAC”), dated Nov. 4, 2021 [dkt. no. 351].) 3 28 U.S.C. § 1406(a) provides that if a case is filed in an improper venue, the Court “shall dismiss, or if it be in the interest of justice, transfer such case to any district . . . in which it could have been brought.” 28 U.S.C. § 1406(a). 4 (See Pl. Dr. Jonathan Berall’s Resp. to Teleflex’s Mot. to Dismiss (“Opp.”), dated Dec. 30, 2021 [dkt. no. 374].) 5 (See Teleflex’s Reply in Supp. of Its Mot. to Dismiss or Alternatively to Transfer Venue in Resp. to Pl’s. Second Am. Compl. (“Reply”), dated Jan. 13, 2022 [dkt. no. 385].) transferred to the Eastern District of North Carolina pursuant to 28 U.S.C. § 1406(a). I. Background Unless otherwise noted, the facts are drawn from the Second Amended Complaint (“SAC”) and are construed in the light most favorable to Plaintiff. See, e.g., Phillips v. Audio Active

Ltd., 494 F.3d 378, 384 (2d Cir. 2007). The Court also considers facts outside of the pleadings, including affidavits. See, e.g., Shepherd v. Annucci, 921 F.3d 89, 95 (2d Cir. 2019) (noting that for a motion to dismiss under Rule 12(b)(3), parties may submit affidavits to demonstrate lack of venue). a. Procedural History Plaintiff commenced the instant action on July 30, 2010, alleging infringement of United States Patent No. 5,827,178 (“the ‘178 Patent”) by, among other defendants, LMA North America, Inc. (“LMA”) for its activities concerning video laryngoscopes.6 (See dkt. no. 1; SAC ¶ 19.) On May 11, 2011,

the Court stayed proceedings pending the United States Patent and Trademark Office’s (the “PTO”) reexamination of the ‘178 Patent. (See dkt. no. 78; SAC ¶ 23.)

6 Plaintiff alleged that “[o]n information and belief, LMA is the exclusive United States distributor for Aircraft’s video laryngoscopes, including, for example, the McGrath Series 5 video laryngoscope.” (Dkt. no. 1 ¶ 16.) During the stay, on December 31, 2013, LMA merged with and into Teleflex, with the latter surviving.7 LMA filed a supplemental Rule 7.1 statement informing the Court and the parties of its acquisition by Teleflex on April 21, 2020. (See dkt. no. 154.) Four days prior, LMA notified the Court that it may advance a defense of improper venue considering the Supreme

Court’s decision in “TC Heartland, LLC v. Kraft Foods Group Brands, 137 S. Ct. 1514 (2017) and may move to transfer at the earliest opportunity.” (Dkt. no. 153.) On November 12, 2020, Plaintiff filed his First Amended Complaint (“FAC”) (dkt. no. 193); however, the “FAC did not amend Dr. Berall’s allegations as to LMA” because “the stay remained in place as to LMA.”8 (See id.; SAC ¶¶ 27, 28.) LMA answered the FAC on December 15, 2020, and did not contest venue, stating: “solely to conserve the resources of the parties and the Court, LMA does not contest venue in this judicial district solely for the purposes of this action.” (Dkt. no. 213

¶ 11.)

7 (See Decl. of Jonathan R. Wise in Supp. of Def. Teleflex Med. Inc.’s Mot. to Dismiss or Alternatively to Transfer Venue in Resp. to Pl’s. Second Am. Compl., dated Dec. 2, 2021 [dkt. no. 360] Ex. C.) 8 In 2020, Dr. Berall notified Teleflex that he “intended to assert that Teleflex’s activities related to . . . Airtraq video laryngoscopes, infringed the ‘178 Patent” (SAC ¶ 126); however, Plaintiff did not assert these claims until filing the SAC. (Dkt. no. 1; FAC; SAC ¶ 126.) The Court lifted the stay as to LMA on December 1, 2020. (See dkt. no. 207; SAC ¶ 30.) On January 19, 2021, the Court granted Plaintiff’s motion to substitute Teleflex for LMA. (See dkt. no. 234; SAC ¶ 32.) On February 12, 2021, Teleflex (as LMA’s successor-in-interest) filed a motion for summary judgment “of non-infringement based on patent exhaustion of the accused

products that LMA distributed for Aircraft . . . .” (Dkt. no. 257 at 14; see also dkt. no. 255.) The Court denied Teleflex’s motion on September 13, 2021. (See dkt. no. 334.) The Court granted Plaintiff’s request to file a Second Amended Complaint on November 1, 2021, (see dkt. no. 350), which Plaintiff filed on November 4, 2021. (See SAC.) In the SAC, Plaintiff included—for the first time—allegations against Teleflex as an entity separate from its interest in LMA. (See SAC.) Specifically, Plaintiff alleges that Teleflex infringed the ‘178 Patent through Teleflex’s distribution of Airtraq laryngoscopes manufactured by Prodol Meditec S.A.9 (See id.

¶¶ 54-63, 81-82.) Teleflex moved to dismiss the SAC on December 2, 2021. (See MTD.) The parties primarily dispute the following issues: (1) whether venue over Teleflex (both as LMA’s successor-in-

9 Teleflex became “the exclusive United States distributor for Airtraq video laryngoscopes [] in 2015,” two years after LMA merged into Teleflex. (SAC ¶ 16.) interest and as a separate entity) is proper in the Southern District of New York (this “District”); (2) whether Teleflex waived its venue objection; and (3) whether Teleflex forfeited its venue challenge by participating in this litigation. The Court addresses each issue in turn. II. Legal Standards

In a patent infringement action, venue is governed by the patent venue statute, 28 U.S.C. § 1400(b). See TC Heartland LLC v. Kraft Foods Grp. Brands LLC, 137 S. Ct. 1514, 1519-21 (2017). “Whether venue is proper under § 1400(b) is an issue unique to patent law and is governed by Federal Circuit law.”10 In re ZTE (USA) Inc., 890 F.3d 1008, 1012 (Fed. Cir. 2018) (citation omitted). “[U]pon motion by the Defendant challenging venue in a patent case, the Plaintiff bears the burden of establishing proper venue.” Id. at 1013. Pursuant to 28 U.S.C. § 1400(b), “[a]ny civil action for patent infringement may be brought in the judicial district

[i] where the defendant resides, or [ii] where the defendant has committed acts of infringement and has a regular and established place of business.” 28 U.S.C. § 1400(b). In applying the

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Christianson v. Colt Industries Operating Corp.
486 U.S. 800 (Supreme Court, 1988)
Autogenomics, Inc. v. Oxford Gene Technology Ltd.
566 F.3d 1012 (Federal Circuit, 2009)
Phillips v. Audio Active Ltd.
494 F.3d 378 (Second Circuit, 2007)
Chirag v. MT Marida Marguerite Schiffahrts
604 F. App'x 16 (Second Circuit, 2015)
Blakely v. Lew
607 F. App'x 15 (Second Circuit, 2015)
TC Heartland LLC v. Kraft Foods Group Brands LLC
581 U.S. 258 (Supreme Court, 2017)
In Re: Cray Inc.
871 F.3d 1355 (Federal Circuit, 2017)
In Re: Micron Technology, Inc.
875 F.3d 1091 (Federal Circuit, 2017)
In Re: Zte (Usa) Inc.
890 F.3d 1008 (Federal Circuit, 2018)
In Re: Oath Holdings Inc.
908 F.3d 1301 (Federal Circuit, 2018)
Andra Group, Lp v. Victoria's Secret Stores, LLC
6 F.4th 1283 (Federal Circuit, 2021)
Celgene Corporation v. Mylan Pharmaceuticals Inc.
17 F.4th 1111 (Federal Circuit, 2021)
Daniel v. American Board of Emergency Medicine
428 F.3d 408 (Second Circuit, 2005)
Shepherd v. Annucci
921 F.3d 89 (Second Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Berall v. Verathon Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/berall-v-verathon-inc-nysd-2022.